NOBUSHIRO NISHIMURA

Dr. NOBUSHIRO NISHIMURA

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
NNNOBUSHIRO NISHIMURA
NOBUSHIRO NISHIMURA
KYKiyomi Yoshimoto
Kiyomi Yoshimoto
NYNoritaka Yada
Noritaka Yada
AKAyaka Kakiwaki
Ayaka Kakiwaki
ASAkihiro Sawa
Akihiro Sawa
KNKenji Nishio
Kenji Nishio
In some cases, differentiating thrombotic thrombocytopenic purpura (TTP) from septic disseminated intravascular coagulation (DIC) without measuring ADAMTS13 activity is critical for urgent lifesaving plasma exchange. To investigate whether PLASMIC score without identifying the presence of schistocytes, D-dimer, fibrin/fibrinogen degradation products (FDP), FDP/D-dimer ratio, prothrombin time-international normalized ratio (PT-INR), lactate dehydrogenase (LD), hemoglobin (Hb), and LD/Hb ratio are useful in differentiating patients with TTP from those with septic DIC. Retrospective analysis was conducted on the medical records of the patients with septic DIC (32 patients) or TTP (16 patients). The PLASMIC score and other laboratory measurements all were helpful in differentiating TTP from septic DIC. When dichotomized between high risk (scores 6–7) and intermediate–low risk (scores 0–5), the PLASMIC score predicted TTP with a sensitivity of 75.0% and a specificity of 100%. However, 4 of 16 patients with TTP and 19 of 32 patients with septic DIC showed comparable PLASMIC scores of 4 or 5, making it difficult to distinguish between the two by PLASMIC score alone. Among the measurements examined, the LDH/Hb ratio was the most useful for differentiation. Receiver operating characteristic analysis of the LD/Hb ratio for predicting TTP revealed a cutoff of 53.7 (IU/10 g) (sensitivity 0.94, specificity 0.91). If the LD/Hb ratio was less than 53.7, it was unlikely that the patient had TTP. A combination of the LD/Hb ratio and the PLASMIC score may be useful for distinguishing between TTP and DIC and identifying patients who need rapid plasma exchange or caplacizumab administration.

1 January 2024 in International Medical Case Reports Journal
Verified
Journal Article
Open access
PDF file
SOShiro Ono
Shiro Ono
KYKiyomi Yoshimoto
Kiyomi Yoshimoto
MMMasaki Matsubara
Masaki Matsubara
NNNOBUSHIRO NISHIMURA
NOBUSHIRO NISHIMURA
HKHiromasa Kawashima
Hiromasa Kawashima
KNKenji Nishio
Kenji Nishio
Purpose: This study aims to investigate the characteristics of Epstein–Barr virus associated-hemophagocytic lymphohistiocytosis (EBV-HLH) and HLH caused by a severe form of infectious mononucleosis (IM-HLH) compared to IM by EBV, and thus also to assist in early diagnosis and providing appropriate treatment. Methods: Data for this analysis were collected from patients at the Department of General Medicine, Nara Medical University, between April 1, 2012, and August 1, 2020. EBV infection was diagnosed using clinical presentation and laboratory tests. HLH diagnosis followed the HLH-2004 protocol, supplemented by plasma EBV DNA detection. A range of clinical and laboratory parameters were collected, including age, sex, clinical outcomes, blood cell counts, hemoglobin, platelets, and various serum values. Plasma EBV DNA levels and flow cytometric analysis (FCM) of bone marrow were performed for HLH cases. Results: Among 1850 hospitalized patients, 14 cases were identified, including 2 HLH cases and 12 IM cases. Comparative analysis revealed distinctive features of HLH, including lower lymphocyte and platelet counts and higher levels of ferritin, soluble interleukin 2 receptor (sIL-2R), and D dimer compared to IM. Notably, one HLH case responded well to corticosteroid monotherapy, while the other case did not, resulting in a fatal outcome. Detection of a cluster of CD5-CD7 lymphocytes in bone marrow is a hallmark of EBV-HLH and useful to distinguish from IM-HLH. Conclusion: This study underscores the importance of early differentiation among EBV-HLH, IM-HLH, and IM in adults to guide appropriate treatment strategies. While specific laboratory markers help distinguish HLH from IM, a more detailed analysis of FCM is crucial for precise diagnosis of HLH cases and tailored therapeutic interventions.

9 October 2025 in Modern Rheumatology
Verified
Journal Article
Closed access
SOShiro Ono
Shiro Ono
TNTomohiro Nakamura
Tomohiro Nakamura
NNNOBUSHIRO NISHIMURA
NOBUSHIRO NISHIMURA
HMHidetoshi Matsuoka
Hidetoshi Matsuoka
RYRyo Yoneima
Ryo Yoneima
KYKiyomi Yoshimoto
Kiyomi Yoshimoto
Objective: This study aimed to evaluate treatment outcomes, complications, and the clinical course of thrombocytopenia in patients with TAFRO syndrome. Methods: We conducted a retrospective analysis of patients treated at Nara Medical University Hospital from 2015 to 2023. Diagnosis of TAFRO syndrome was made according to the 2015 or 2019 criteria, and disease severity was assessed based on the updated disease severity classification. Clinical characteristics and laboratory and histological data were analysed. Results: Seven patients were included, with four classified as very severe, two as severe, and one as slightly severe. All the patients received early combination therapy (various combinations of glucocorticoids, tocilizumab, cyclosporine, and rituximab), with the second therapy added a median of 5 days after the first. Six patients received eltrombopag. Despite intensive treatment, thrombocytopenia persisted for a prolonged period, with a median time to platelet count normalization of 54 days. Cytomegalovirus reactivation occurred in six patients during treatment but resolved with appropriate antiviral therapy. All the patients achieved remission and survived. Conclusions: Thrombocytopenia in TAFRO syndrome persists long term despite intensive combination therapy. Early combination therapy was associated with excellent survival outcomes, suggesting that intensifying treatment solely for thrombocytopenia may not be necessary given its prolonged course.

20 January 2026 in Medicina
Verified
Journal Article
Open access
PDF file
RYRyo Yoneima
Ryo Yoneima
KNKenji Nishio
Kenji Nishio
HKHiromasa Kawashima
Hiromasa Kawashima
SSSota Sakamoto
Sota Sakamoto
TNTomohiro Nakamura
Tomohiro Nakamura
KYKiyomi Yoshimoto
Kiyomi Yoshimoto
Background and Objectives: The Dix–Hallpike test (DHT) is the standard diagnostic maneuver for posterior semicircular canal benign paroxysmal positional vertigo (BPPV). However, some patients present with positional symptoms compatible with BPPV yet show no observable nystagmus on the DHT. We introduced the Head Rotation Sit-up Test (HRST) as a symptom-based maneuver and hypothesized that it would identify DHT-negative patients who nonetheless benefit from canalith repositioning. This study aimed to explore the potential role of the HRST. It was introduced as a complementary, symptom-based maneuver for evaluating non-classical vertigo presentations. Materials and Methods: We retrospectively reviewed patients clinically suspected of having BPPV by the attending physicians at Nara Medical University Hospital (August 2018–July 2022). All underwent both the DHT and HRST; those positive on either test received the Epley maneuver and were included. Patients were categorized as Group 1: DHT(−)/HRST(+), and Group 2: DHT(+), irrespective of the HRST, for the purpose of comparing patients who were positive on the HRST with those positive on the DHT. Post-treatment symptom severity was assessed on a 0–10 scale, with the patient’s most severe pre-treatment symptom defined as 10, and responder rates (post-Epley score < 5) were compared. Results: Among 179 patients with suspected BPPV, 80 were test-positive and were treated with the Epley maneuver. Group 1 comprised 31 patients, who more commonly reported non-rotational symptoms such as floating or unsteadiness, whereas rotational vertigo predominated in Group 2 (n = 49). Median post-Epley scores were significantly lower after treatment in both groups (Group 1: 2 [IQR 0–3]; Group 2: 3 [IQR 0–5]). Group 1 demonstrated a higher responder rate than Group 2 (90.3% vs. 65.3%, p = 0.016). Within Group 2, outcomes did not differ significantly between DHT(+)/HRST(+) and DHT(+)/HRST(−) subgroups. Conclusions: The HRST identified a clinically relevant subgroup of DHT-negative patients who nevertheless responded favorably to the Epley maneuver. Incorporating the HRST alongside the DHT may expand the diagnostic reach for BPPV, particularly among patients with non-classical symptoms or without observable nystagmus. These findings support the HRST as a useful complementary maneuver for detecting Epley responsive, symptom based positional vertigo.

29 June 2026 in Modern Rheumatology Case Reports
Verified
Journal Article
Closed access
MAMoe Asada
Moe Asada
MMMasaki Matsubara
Masaki Matsubara
YUYoshinori Uenishi
Yoshinori Uenishi
YHYuki Hatta
Yuki Hatta
NNNOBUSHIRO NISHIMURA
NOBUSHIRO NISHIMURA
KYKiyomi Yoshimoto
Kiyomi Yoshimoto
Pustulotic arthro-osteitis (PAO) is a chronic inflammatory disorder associated with palmoplantar pustulosis (PPP) and characterised by osteoarticular manifestations. Although several immune-mediated comorbidities have been reported in association with PPP/PAO, polyarteritis nodosa occurring in patients with PPP/PAO has not been described previously. We report a case of a 56-year-old woman with a long-standing history of PPP and PAO who developed worsening osteoarticular symptoms in close temporal proximity to purpura, lower-extremity pain, and sensory disturbance, followed by paraesthesia in the fingers. Neurological examination revealed mild weakness of the left tibialis anterior muscle. Laboratory testing showed elevated inflammatory markers, whereas myeloperoxidase- and proteinase 3-antineutrophil cytoplasmic antibodies were negative. Musculoskeletal imaging revealed bilateral sternoclavicular joint synovitis, inflammatory changes adjacent to the right patellar tendon insertion with infrapatellar bursitis, and right peroneal tenosynovitis. Nerve conduction studies in the lower extremities suggested mononeuritis multiplex. A skin biopsy of a purpuric lesion demonstrated fibrinoid necrosis and inflammatory infiltration in medium-sized arteries within the subcutaneous tissue. The patient was diagnosed with an exacerbation of PAO complicated by polyarteritis nodosa and was treated with oral prednisolone followed by methotrexate, resulting in rapid normalisation of inflammatory markers and improvement in osteoarticular symptoms, purpura, and finger paraesthesia, although lower-extremity neurological symptoms persisted at discharge. When patients with PAO develop atypical features such as purpura or neuropathic symptoms suggestive of mononeuritis multiplex, concomitant vasculitis, including polyarteritis nodosa, should be considered in the differential diagnosis.